Regen Biopharma issues 77.85M shares to settle $68,723 in debt and fees

Regen BioPharma Inc

Issued 77,849,847 common shares between Feb 4-27, 2026 for $53,474 principal, $4,249 interest, $11,000 fees.
Shares were issued in unregistered private placement under Section 4(a)(2) with no underwriter or commission.
Post-issuance outstanding shares total 212,318,424 as of March 3, 2026.
Implied issuance price of approximately $0.0009 per share, suggesting severe dilution for existing holders.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.9

Regen BioPharma Inc issued 77,849,847 common shares of common stock for satisfaction of $53,474 of principal convertible indebtedness, $4,249 of accrued interest on convertible indebtedness and $11,000 in incurred fees.

Security: common stock
Shares: 77,849,847 common shares
Consideration: satisfaction of $53,474 of principal convertible indebtedness, $4,249 of accrued interest on convertible indebtedness and $11,000 in incurred fees

Exact text from the filing

Between February 4, 2026 and February 27, 2026 the Company issued 77,849,847 common shares (“Shares”) in satisfaction of $53,474 of principal convertible indebtedness, $4,249 of accrued interest on convertible indebtedness and $11,000 in incurred fees.

View on SEC.gov

Browse all equity issuances →

Regen BioPharma Inc filing history →

Source: SEC EDGAR

accession 0001493152-26-008837

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.